Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments 
worldwide. Aina and colleagues assessed the safety and activity of 
ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma. 
https://pubmed.ncbi.nlm.nih.gov/37414060/

ALSO AS VIDEO ON
https://youtu.be/Ymgg22roWGU

CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari

#17 Nathanial Anderson: Signatures and persistence of CAR-T cells

Welcome to “Trainee Pearls”, a new initiative brought to you by the EBMT Trainee Committee to deliver the most important messages (“the pearls”) of high-profile research works in hematology and bone marrow transplant to our fellow trainees all over the world. The topics will span from classical hematology to more focused bone marrow transplant research. The selected research article will be discussed directly with young authors who have been involved with the published work.